论文部分内容阅读
目的 探讨Ir192 腔内近距离放疗结合顺铂膀胱灌注预防膀胱癌术后复发的疗效。方法 综合组Ir192 腔内近距离放疗结合顺铂膀胱灌注与对照组单纯PDD膀胱灌注预防膀胱癌术后复发进行随机对照观察。结果 综合组2 5例 ,对照组 2 0例 ,均随访 12～ 3 6个月。综合组 1年无癌生存率 85 % ,复发率 15 %。 3年无癌生存率 64 % ,复发率3 6%。对照组 1年无癌生存率 75 % ,复发率 2 5 %。 3年无癌生存率 5 0 % ,复发率 5 0 %。结论 Ir192 腔内近距离放疗结合顺铂膀胱灌注预防膀胱癌术后复发的疗效优于单纯顺铂膀胱灌注
Objective To investigate the efficacy of Ir192 intra-brachytherapy combined with cisplatin intravesical instillation to prevent postoperative recurrence of bladder cancer. Methods Ir192 intracavitary brachytherapy combined with cisplatin intravesical instillation and PDD bladder perfusion in the control group were used to prevent recurrence of bladder cancer after randomized controlled study. Results A total of 25 patients in the combined group and 20 in the control group were followed up for 12 to 36 months. Comprehensive group 1 year cancer-free survival rate of 85%, the recurrence rate of 15%. 3 years cancer-free survival rate 64%, the recurrence rate 36%. The control group had a 1-year cancer-free survival rate of 75% and a recurrence rate of 25%. 3 years without cancer survival rate of 50%, recurrence rate of 50%. Conclusion Ir192 intracavitary brachytherapy combined with cisplatin intravesical instillation of bladder cancer prevention of recurrence after curative effect is better than cisplatin bladder perfusion